Trial Profile
First-in-human, Randomised, Double-blind, Placebo-controlled, Dose-escalation Study in Healthy Young Adults Evaluating the Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Candidate for Prevention of COVID-19
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs CDX 005 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors Codagenix
- 24 Jun 2022 Status changed from active, no longer recruiting to completed.
- 17 Mar 2022 Interim results presented in a Codagenix media release.
- 29 Sep 2021 Results presented in the Codagenix Media Release.